You Gotta See What We Found On GNTA

On August 1, 2012, in Daily Watchlist, by

Good morning readers and welcome new subscribers!

The market is about to open on this beautiful Wednesday so lets get right into it! What we’ve uncovered through our daily research about this stock has us completely blown away! If you read any part of this email, make sure it is the excerpt from the SEC filing that warranted this entire alert.

Wednesday’s triple zero “early-bird” alert is:

GNTA - Genta Inc.

Genta Incorporated is a bio-pharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company is developing tesetaxel, a novel, orally absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel. As the leading oral taxane in clinical development, tesetaxel is being evaluated in randomized clinical trials that compare tesetaxel with standard chemotherapy in patients with gastric cancer and breast cancer, and as a single agent in prostate cancer.

Why are we looking at GNTA today?

You know we never stop working to bring our members a new trade idea and what we found tucked away in an SEC filing from Monday night has us anxious to share our findings with you!

Monday night (July 30th) GNTA filing this 8K SEC Filing disclosing a certain company event.

On July 30, 2012 , Genta Incorporated (the “Company”) announced that it has received formal notice from the drug regulatory authority of the People’s Republic of China (SFDA) that the Company has received approval to start clinical trials with tesetaxel, its lead clinical compound, in China .

SFDA has requested and approved a dose-ranging study of the combination of capecitabine plus tesetaxel, up to and including the dose used in a pivotal randomized trial (known as TESEGAST), as well as subsequent participation by China in the TESEGAST study. The TESEGAST study is designed to evaluate the safety and activity of tesetaxel plus capecitabine compared with capecitabine plus placebo in patients with advanced gastric cancer. Gastric cancer is the second most common tumor type in China .

Not only is this News INCREDIBLE, GROUND-BREAKING, and GAME-CHANGING…it has not even been formally released and distributed via press release yet!!

You are amongst the FIRST to see this news and you can thank us for that! GNTA now has the opportunity to enter the most populated country in the World - China - with the Approval by the Chinese SFDA to begin clinical trials!

Make sure you’re watching GNTA today! We have seen many stocks run on similar news in the past - how will GNTA react once the public finds out about this piece of info?

Comments are closed.

What are you waiting for?